Summary
The purpose of the study was to determine prognostic significance of pretreatment serum levels of different molecules involved in cell to cell interactions along with other clinical parameters in patients with metastatic renal cell carcinoma. sICAM-1, sVCAM-1 and sELAM-1 serum levels were determined by ELISA assays in sera from 99 patients with histologically confirmed progressive metastatic renal cell carcinoma prior to initiation of systemic therapy. Kaplan–Meier survival analysis, log-rank statistics and two-proportional Cox regression analyses were employed to identify risk factors and to demonstrate statistical independence. In univariate analyses, the following pretreatment risk factors could be identified: serum sICAM-1 level > 360 ng ml–1, erythrocyte sedimentation rate > 70 mm h–1, serum C-reactive protein level > 8 mg l–1, serum lactic dehydrogenase level > 240 U/ l and neutrophil count > 6000 μl–1. Multivariate analyses demonstrated statistical independence for serum sICAM-1 level, erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level as pretreatment predictors of overall patient survival. The prognostic significance of sICAM-1 might indicate a role of this molecule for tumour progression, potentially in association with the abrogation of anti-tumour immune responses. The possibility of defining a pretreatment risk model based on sICAM-1 level, ESR and CRP also warrants further investigation, with regard to a possible linkage between acute phase proteins and sICAM-1 levels.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Amblard, F., Auffray, C., Sekaly, R. & Fischer, A. (1994). Molecular analysis of antigen-independent adhesion forces between T and B lymphocytes. Proc Natl Acad Sci USA 91: 3628–3632.
Anastassiou, G., Duensing, S., Steinhoff, G., Kirchner, H., Ganser, A. & Atzpodien, J. (1995). In vivo distribution of integrins in renal cell carcinoma: integrin-phenotype alteration in different degrees of tumor differentiation and VLA-2 involvement in tumor metastases. Cancer Biother 10: 287–292.
Atzpodien, J., Körfer, A., Franks, C., Poliwoda, H. & Kirchner, H. (1990). Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335: 1509
Becker, J. C., Termeer, C., Schmidt, R. E. & Bröcker, E-B (1993). Soluble intercellular adhesion molecule 1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151: 7224–7232.
Boyd, A. W., Wawryk, S. O., Burns, G. F. & Fecondo, J. V. (1988). Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell–cell contact mediated immune mechanisms. Proc Natl Acad Sci USA 85: 3095–3099.
Chong, A. S., Boussy, I. A., Jiang, X. L., Lamas, M. & Graf, L. H. Jr (1994). CD54/ICAM-1 is a costimulator of NK-mediated cytotoxicity. Cell Immunol 157: 92–105.
Christiansen, I., Enblad, G., Kalkner, K. M., Gidlof, C., Glimelius, B. & Töttermann, T. (1995). Soluble ICAM-1 in Hodgkins disease: a promising independent predictive marker for survival. Leuk Lymphoma 19: 243–251.
Christiansen, I., Gidlof, C., Kalkner, K. M., Hagberg, H., Bennmarker, H. & Tötermann, T. (1996). Elevated serum levels of soluble ICAM-1 in non-Hodgkins lymphoma correlates with tumor burdon, clinical activity, and other prognostic markers. Br J Haematol 92: 639–646.
Fecondo, J. V., Kent, S. B. & Boyd, A. W. (1991). Inhibition of intercellular adhesion molecule 1 dependent biological activities by a synthetic peptide analog. Proc Natl Acad Sci USA 88: 2879–2882.
Foreman, N. K., Rill, D. R., Coustan-Smith, E., Douglass, E. C. & Brenner, M. K. (1993). Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for minimal disease eradication. Br J Cancer 67: 933–938.
Franzke, A., Probst-Kepper, M., Buer, J., Duensing, S., Hoffmann, R., Wittke, F., Volkenandt, M., Ganser, A. & Atzpodien, J. (1998). Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78: 40–45.
Hatzistilianou, M., Athanassiadou, F., Agguridaki, C. & Catriu, D. (1997). Circulating soluble adhesion molecule levels in children with acute lymphoblastic leukemia. Eur J Pediatr 156: 537–540.
Heicapell, R., Podlinski, J., Buszello, H. & Ackermann, R. (1994). Cell surface expression and serum levels of intercellular adhesion molecule 1 in renal cell carcinoma. Urol Res 22: 9–15.
Ljungberg, B., Grankvist, K. & Rasmuson, T. (1995). Acute phase reactants and prognosis in renal cell carcinoma. Cancer 76: 1435–1439.
Maio, M., Pinto, A., Carbone, A., Zagonel, V., Gloghini, A., Marotta, G., Cirillo, D., Colombatti, A., Ferrara, F. & Del-Vecchio, L. (1990). Differential expression of CD54/intercellular adhesion molecule 1 im myeloid leukemias and lymphoproliferative disorders. Blood 76: 783–790.
Makgoba, M. W., Sanders, M. E., Ginther Luce, G. E., Gugel, E. A., Dustin, M. L., Springer, T. A. & Shaw, S. (1988). Functional evidence that intercellular adhesion molecule 1 (ICAM-1) is a ligand for LFA-1 dependent adhesion in T-cell mediated cytotoxicity. Eur J Immunol 18: 637–640.
Marlin, S. D. & Springer, T. A. (1987). Purified intercellular adhesion molecule 1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813–819.
Meyer, D. M., Dustin, M. L. & Carron, C. P. (1995). Characterization of intercellular adhesion molecule 1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function associated molecule 1 interaction with ICAM-1. J Immunol 155: 3578–3584.
Moy, V. T. & Brian, A. A. (1992). Signaling by lymphocyte function associated antigen 1 (LFA-1) in B-cells: enhanced antigen presentation after stimulation through LFA-1. J Exp Med 175: 1–7.
Natali, P., Nicotra, M. R., Cavaliere, R., Bigotti, A., Romano, G., Temponi, M. & Ferrone, S. (1990). Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 50: 1271–1278.
Natali, P. G., Hamby, C. V., Felding-Habermann, B., Liang, B., Nicotra, M. R., Di-Filippo, F., Giannarelli, D., Temponi, M. & Ferrone, S. (1997). Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule 1 expression in cutaneous malignant melanoma lesions. Cancer Res 57: 1554–1560.
Passlick, B., Izbicki, J. R., Simmel, S., Kubuschok, B., Karg, O., Habekost, M., Thetter, O., Schweiberer, L. & Pantel, K. (1994). Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule 1 on operable non small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 30A: 376–381.
Reinhardt, K. M., Steiner, M., Zillig, D., Nagel, H. R., Blann, A. D. & Brinckmann, W. (1996). Soluble intercellular adhesion molecule 1 in colorectal cancer and its relationship to acute phase proteins. Neoplasma 43: 65–67.
Roit, I., Brostoff, J. & Male, D. (1996). Immunology, 4th edn. Mosby: London
Rothlein, R., Mainolfi, E. A., Czaikowski, M. & Marlin, S. D. (1991). A form of circulating ICAM-1 in human serum. J Immunol 147: 3788–3739.
Schadendorf, D., Diehl, S., Zuberbier, T., Schadendorf, C. & Henz, B. M. (1996). Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 192: 89–93.
Shimizu, Y., Minemura, M., Tsukishiro, T., Kashii, Y., Miyamoto, M., Nishimori, H., Higuchi, K. & Watanabe, A. (1995). Serum concentration of intercellular adhesion molecule 1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 22: 525–531.
Sung, K. L., Kuhlmann, P., Maldonado, F., Lollo, B. A., Chien, S. & Brian, A. A. (1992). Force contribution of the LFA-1/ICAM-1 complex to T cell adhesion. J Cell Sci 103: 259–266.
Van den Stolpe, A. & van der Saag, P. T. (1996). Intercellular Adhesion Molecule 1. J Mol Med 74: 13–33.
Vora, A. R., Rodgers, S., Parker, A. J., Start, R., Rees, R. C. & Murray, A. K. (1997). An immunohistochemical study of altered immunomodulary molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76: 836–844.
Welder, C. A., Lee, D. H. & Takei, F. (1993). Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule 1. J Immunol 150: 2203–2210.
Wolff, J. M., Stephenson, R. N., Chisholm, G. D. & Habib, F. K. (1995). Levels of circulating intercellular adhesion molecule 1 in patients with metastatic cancer of the prostate and benign prostate hyperplasia. Eur J Cancer 31A: 339–341.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hoffmann, R., Franzke, A., Buer, J. et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 79, 1742–1745 (1999). https://doi.org/10.1038/sj.bjc.6690277
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690277
Keywords
This article is cited by
-
Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma
Cancer Immunology, Immunotherapy (2010)
-
Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
British Journal of Cancer (2006)
-
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma
British Journal of Cancer (2006)
-
Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions
British Journal of Cancer (2004)
-
Metastatic renal carcinoma comprehensive prognostic system
British Journal of Cancer (2003)